Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, Waked I, Dore GJ, Abbas Z, Abdallah AR, Abdulla M. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7:396–415.

Article  Google Scholar 

Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45:101596.

Article  PubMed  Google Scholar 

Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013;19:7896–909.

Article  PubMed  PubMed Central  Google Scholar 

Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.

Article  PubMed  Google Scholar 

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192–9.

Article  PubMed  Google Scholar 

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996–1005.

Article  CAS  PubMed  Google Scholar 

Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278–87.

Article  CAS  PubMed  Google Scholar 

Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25–32.

Article  Google Scholar 

Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.

Article  Google Scholar 

Singal AG, Lim JK, Kanwal F. AGA Clinical Practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156:2149–57.

Article  PubMed  Google Scholar 

Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686–721.

Article  PubMed  Google Scholar 

Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458–65.

Article  PubMed  Google Scholar 

Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69:1088–98.

Article  PubMed  PubMed Central  Google Scholar 

Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-Nzinga C, Leroy V, De Ledinghen V, et al. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clin Res Hepatol Gastroenterol. 2022;46:101923.

Article  CAS  PubMed  Google Scholar 

Alonso LS, Manzano ML, Gea F, Gutierrez ML, Ahumada AM, Devesa MJ, Olveira A, et al. A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis. Hepatology. 2020;72:1924–34.

Article  Google Scholar 

Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, et al. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res. 2021;51:860–9.

Article  CAS  PubMed  Google Scholar 

Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DT. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28:96–107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264–78.

Article  CAS  PubMed  Google Scholar 

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70.

Article  PubMed  Google Scholar 

Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368–78.

Article  CAS  PubMed  Google Scholar 

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol. 2013;19:2793–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800–6.

Article  CAS  PubMed  Google Scholar 

Kim JH, Kim YD, Lee M, Jun BG, Kim TS, Suk KT, Kang SH, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69:1066–73.

Article  PubMed  Google Scholar 

Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, et al. Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017;68:92–9.

Article  Google Scholar 

Jepsen P, Kraglund F, West J, Villadsen GE, Sorensen HT, Vilstrup H. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J Hepatol. 2020;73:1030–6.

Article  PubMed  Google Scholar 

Lee HW, Chon YE, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Predicting liver-related events using transient elastography in chronic hepatitis C patients with sustained virological response. Gut Liver. 2016;10:429–36.

Article  PubMed  Google Scholar 

Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis. 2018;50:573–9.

Article  PubMed  Google Scholar 

Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, et al. Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting: a real-life experience. Dig Dis Sci. 2019;64:3013–9.

Article  PubMed  Google Scholar 

Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, et al. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. Liver Int. 2016;36:1793–9.

Article  CAS  PubMed  Google Scholar 

Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, Kato N, Kanai F, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42:839–43.

Article  PubMed  Google Scholar 

Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, et al. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy. J Gastroenterol Hepatol. 2014;29:137–43.

Article  CAS  PubMed  Google Scholar 

Wang JH, Changchien CS, Hung CH, Tung WC, Kee KM, Chen CH, Hu TH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol. 2010;25:964–9.

Article  PubMed  Google Scholar 

Sultanik P, Kramer L, Soudan D, Bouam S, Meritet JF, Vallet-Pichard A, Fontaine H, et al. The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study. Aliment Pharmacol Ther. 2016;44:505–13.

Article  CAS  PubMed  Google Scholar 

Pang JX, Zimmer S, Niu S, Crotty P, Tracey J, Pradhan F, Shaheen AA, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS ONE. 2014;9:e95776.

Article  PubMed  PubMed Central  Google Scholar 

Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.

Article  PubMed  Google Scholar 

Rinaldi L, Perrella A, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med. 2019;17:292.

Article  PubMed  PubMed Central  Google Scholar 

Elsharkawy A, Alem SA, Fouad R, El RM, El AW, Abdo M, Tantawi O, et al. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol. 2017;32:1624–30.

Article  CAS  PubMed